Anti-SELENOI antibodies are used in the immunodetection of the protein selenoprotein I. In humans, the canonical protein has a reported length of 397 amino acid residues and a mass of 45.2 kDa. Its subcellular localization is in the ER. It is widely expressed across many tissue types. A member of the CDP-alcohol phosphatidyltransferase class-I protein family, SELENOI is a reported ethanolaminephosphotransferase that catalyzes the transfer of phosphoethanolamine/PE from CDP-ethanolamine to lipid acceptors, the final step in the synthesis of PE via the 'Kennedy' pathway. The SELENOI gene has been associated with the disease, Spastic paraplegia. Synonyms for this target antigen include ethanolaminephosphotransferase 1 (CDP-ethanolamine-specific), hEPT1, and ethanolaminephosphotransferase 1. SELENOI gene orthologs have been reported in the mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken species. Some SELENOI antibodies may have been used in research and have associated citations. These antibodies are most commonly used in Western Blot experiments, among other applications.